# Best Practices in Developing Proprietary Names for Human Nonprescription Drug Products; Draft Guidance for Industry: Draft Guidance for Industry - FDA Guidance Document Source: https://www.globalkeysolutions.net/guidances/guidance-document/best-practices-in-developing-proprietary-names-for-human-nonprescription-drug-products-draft-guidance-for-industry-draft-guidance-for-industry/5574de95-cac8-42dc-9e8f-20bb345394e6 > FDA guidance document: Best Practices in Developing Proprietary Names for Human Nonprescription Drug Products; Draft Guidance for Industry: Draft Guidance for Industry. Issue date: December 08, 2020. Get complete insights and analysis. --- ## Details - Title: Best Practices in Developing Proprietary Names for Human Nonprescription Drug Products; Draft Guidance for Industry: Draft Guidance for Industry - Communication Type: Guidance Document - Product Type: drugs - Office Name: Center for Drug Evaluation and Research - Office URL: /offices/center-for-drug-evaluation-and-research/cd980d74-1cbf-4226-ba9a-9045324c236c - Issue Date: 2020-12-08 - Comment Close Date: 2021-02-08 - Last Changed: 2020-12-08 - Docket Number: FDA-2020-D-0770 ## Related Documents - [Use of Bayesian Methodology in Clinical Trials of Drug and Biological Products: Draft Guidance for Industry](https://www.globalkeysolutions.net/guidances/guidance-document/use-of-bayesian-methodology-in-clinical-trials-of-drug-and-biological-products-draft-guidance-for-industry/8e9c345e-0994-47b3-8d6c-054f04ed937e) - [Biomarker Qualification: Evidentiary Framework: Draft Guidance for Industry and FDA Staff](https://www.globalkeysolutions.net/guidances/guidance-document/biomarker-qualification-evidentiary-framework-draft-guidance-for-industry-and-fda-staff/c198796d-4230-4499-a6ee-2f84eed424c9) - [Development of a Shared System REMS Guidance for Industry](https://www.globalkeysolutions.net/guidances/guidance-document/development-of-a-shared-system-rems-guidance-for-industry/b67470fa-28bc-4644-aeba-c9afd830c0cd)